Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Parsabiv

- PMLiVE

Abbott stops kidney disease drug trial on safety concerns

Concerns about excess serious adverse events and mortality in patients taking bardoxolone methyl

- PMLiVE

Amgen’s Anna Richo joins UCB as executive VP and general counsel

Meanwhile, Cynthia Patton takes over as Amgen’s senior VP and chief compliance officer

- PMLiVE

NICE stroke guidance boost for Boehringer’s Actilyse

Institute changes guidance on alteplase use

- PMLiVE

Patient access schemes likely to remain under VBP, says NICE

New and existing schemes expected to have place within UK’s new pricing environment

- PMLiVE

AZ pays $273m for Ardelyx renal disease drug

Phase II candidate could tackle fluid overload in kidney and heart disorders

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

A new dogma in HTA assessment

New communication routes to HTA agencies are needed to ensure that these organisations can advise on clinical trial design

- PMLiVE

The bigger picture in medicine value

By focusing on cost are we obscuring the true value of medicines?

Amgen poaches J&J’s Ray Jordan for corporate affairs post

He joins on October, 1 with a strategic communications remit

- PMLiVE

GSK persuades NICE to reconsider negative Benlysta decision

Decision on lupus drug referred to expert committee following appeal

Amgen-Takeda’s ganitumab fails in pancreatic cancer study

Interim analysis shows no improvement in overall survival

UK reaffirms NHS access to NICE-approved drugs

Health Secretary makes pledge on same day Future Forum recommendations on NHS reform accepted

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links